Why We Invested

TerraBlue's founding team — ex-MIT electrochemistry researchers — had a genuine materials science breakthrough that dropped DAC energy consumption by 38% vs. leading incumbent processes. With three utility patents filed and a credible cost roadmap to sub-$100/ton, this was the most technically differentiated carbon removal bet we had seen.

Post-Investment Outcomes

Raised $28M Series A led by Breakthrough Energy Ventures (Q3 2025). First commercial 10,000-ton/year pilot facility operational in West Texas. Cost per ton certified at $142 — 6 months ahead of schedule. Contracted offtake agreements signed with two Fortune 100 companies totaling $45M over 5 years.

Why We Invested

The founder's background building community energy programs at NRDC gave SolarGrid an immediate distribution advantage through 200+ community organizations across low-income markets. The IRA's direct-pay provision for community solar made the unit economics structurally sound for the first time, and SolarGrid was the most operationally sophisticated platform we had evaluated.

Post-Investment Outcomes

Grew from 8,000 to 45,000+ subscriber households in 14 months. Raised $20M Series A co-led by Energy Impact Partners and Generate Capital (Q1 2025). Expanded to 18 states. Average subscriber saves $420/year on energy bills. Partnership with HUD to reach public housing residents across 6 metro areas announced February 2025.

Why We Invested

The SEC's climate disclosure rules and ISSB standards were creating a compliance-driven market that barely existed the year before. ClimateAI's proprietary ensemble modeling approach — combining satellite imagery, hydrological models, and insurance loss data — produced physical risk projections 40% more accurate than incumbent catastrophe modeling firms. The enterprise sales pipeline was already $8M at seed close.

Post-Investment Outcomes

ARR grew 3x in 12 months to $4.2M. Now partnering with 3 of the top 10 global banks and 2 of the top 5 global insurers for portfolio-level physical risk assessment. Raised $24M Series A led by Obvious Ventures and Climate Capital in October 2024. Recognized as a Forrester Emerging Vendor in climate risk analytics, Q4 2024.

Why We Invested

The founding physician-engineer team had lived the rural healthcare infrastructure problem firsthand — one co-founder had practiced in rural Appalachia for 8 years. HealthBridge had already signed MOUs with the National Rural Health Association and HRSA-funded health centers, giving them a distribution channel that no well-funded competitor could replicate from scratch.

Post-Investment Outcomes

Expanded from 40 to 200+ rural facilities in 10 months. Enabling 3M+ specialist consultations annually — conditions that would otherwise require 4+ hour round-trip travel. Raised $22M Series A led by Town Hall Ventures and Optum Ventures in March 2025. Accepted into HHS Health Center Accelerator Program. Average wait time for specialist consult dropped from 6 weeks to 4 days across partner facilities.

Why We Invested

EduPath had independent RCT data from a Stanford Education Lab pilot showing 0.7 SD improvement in reading proficiency — among the strongest effect sizes ever recorded for a digital learning intervention. The product ran on existing school Chromebook infrastructure, removing the device cost barrier that killed most EdTech pilots in Title I settings.

Post-Investment Outcomes

Expanded to 120,000+ students across 15 states. Stanford RCT confirmed 0.9 SD improvement in updated study cohort. Raised $22M Series A led by New Schools Venture Fund and Owl Ventures in January 2025. District renewal rate: 94%. Selected as a Gates Foundation Grand Challenges grantee for personalized learning in under-resourced schools.

Why We Invested

MindSpace addressed a critical gap: existing mental health benefit platforms offered generic therapist directories with no cultural competency matching. The founding clinical psychologist had spent 12 years studying mental health outcomes disparities across racial and ethnic groups, and built matching algorithms validated to deliver 2.3x better therapeutic engagement for Black, Hispanic, and Asian employees vs. generic platforms.

Post-Investment Outcomes

Deployed at 150+ enterprise customers covering 280,000 employees. Absenteeism reduced by 22% and voluntary turnover by 14% among enrolled employees (independently audited). ARR reached $8.4M with 130% NRR. Raised $18M Series A led by General Catalyst and 7wireVentures in November 2024.

Why We Invested

Metabolic disease costs US employers over $210 billion annually in healthcare claims and lost productivity. NutriSync's multi-modal approach — combining CGM data, microbiome sequencing, and behavioral coaching — was validated in a 400-person RCT showing 40% reduction in metabolic disease risk markers, making it the strongest clinical evidence we had seen in digital health.

Post-Investment Outcomes

Pivoted successfully from DTC to enterprise health benefits in 2023. Now deployed at 150+ enterprise customers. Average employer saves $1,800/year per enrolled employee in reduced healthcare claims. ARR reached $6.2M in Q4 2024. Series A process ongoing; $25M target with lead investor in diligence.

Why We Invested

Ex-USDA soil scientist co-founder brought 15 years of proprietary soil modeling expertise — her prediction accuracy of 94% on irrigation timing was the highest we had independently verified in agritech. The SMS-based delivery architecture made the platform viable for low-bandwidth emerging markets from day one, opening a TAM most competitors couldn't access.

Post-Investment Outcomes

Grew from 500 to 80,000 active farms in 24 months. $240M in cumulative annual farmer input savings. Raised $18M Series A led by Breakthrough Energy Ventures (October 2024) plus $4.2M Gates Foundation grant for West Africa expansion. Expanded to Ghana and Senegal with CGIAR data partnership. Target: 500,000 farms by 2027.

Why We Invested

VerdantFoods' proprietary microbial strain library — developed over 7 years of academic research at UC Davis — gave them a production cost structure 30% below any competing precision fermentation platform. The founding team had also secured a long-term contract manufacturing agreement with a major bioreactor operator, de-risking the scale-up pathway that kills most food tech companies.

Post-Investment Outcomes

Converted 3 LOIs into signed supply agreements with Ingredion, Kerry Group, and a major private-label food manufacturer. Commissioned first commercial-scale fermentation facility with 2,000-ton annual capacity. Raised $32M Series A led by AgFunder and DCVC Bio in February 2025. Price parity milestone projected for Q3 2026, ahead of original 2027 target.

Why We Invested

Less than 5% of global industrial waste flows were being managed through digital platforms when we invested — the rest was phone-and-spreadsheet coordination. CircleEcon's real-time materials exchange, compliance documentation engine, and carrier network gave industrial buyers a 10-day reduction in average waste-to-recycler cycle time, creating hard ROI alongside the environmental benefit. EU EPR regulations were creating a regulatory tailwind no European manufacturer could ignore.

Post-Investment Outcomes

GMV grew from $18M to $120M+ in 18 months. Processing 180,000+ tons annually across 22 countries. Raised $38M Series B led by Prelude Ventures and Blue Earth Capital in Q4 2024. Net revenue retention: 148%. Scope 3 reporting integration launched — now embedded in SAP and Oracle ERP workflows for 80+ enterprise customers.